Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | CX-5461 |
| Synonyms | |
| Therapy Description |
CX-5461 is an RNA polymerase I (Pol I) inhibitor that inhibits rRNA synthesis, resulting in growth arrest and apoptosis in cancer cells (PMID: 26472108). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CX-5461 | CX5461 | CX-5461 is an RNA polymerase I (Pol I) inhibitor that inhibits rRNA synthesis, resulting in growth arrest and apoptosis in cancer cells (PMID: 26472108, PMID: 32719798). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRIP1 A349P | Advanced Solid Tumor | sensitive | CX-5461 | Preclinical - Cell culture | Actionable | In a preclinical study, CX-5461 inhibited survival of transformed cells expressing BRIP1 A349P in culture (PMID: 32542039). | 32542039 |
| BRIP1 K52R | Advanced Solid Tumor | sensitive | CX-5461 | Preclinical - Cell culture | Actionable | In a preclinical study, CX-5461 inhibited survival of transformed cells expressing BRIP1 K52R in culture (PMID: 32542039). | 32542039 |
| BRIP1 C283R | Advanced Solid Tumor | sensitive | CX-5461 | Preclinical - Cell culture | Actionable | In a preclinical study, CX-5461 inhibited survival of transformed cells expressing BRIP1 C283R in culture (PMID: 32542039). | 32542039 |
| BRIP1 M299I | Advanced Solid Tumor | no benefit | CX-5461 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing BRIP1 M299I were not sensitive to CX-5461 induced growth inhibition in culture (PMID: 32542039). | 32542039 |
| BRIP1 L340F | Advanced Solid Tumor | no benefit | CX-5461 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing BRIP1 L340F were not sensitive to CX-5461 induced growth inhibition in culture (PMID: 32542039). | 32542039 |
| BRIP1 del | Advanced Solid Tumor | sensitive | CX-5461 | Preclinical - Cell culture | Actionable | In a preclinical study, CX-5461 inhibited survival of transformed cells with BRIP1 knocked out by CRISPR/Cas9 in culture (PMID: 32542039). | 32542039 |
| PTEN loss | prostate cancer | no benefit | CX-5461 | Preclinical | Actionable | In a preclinical study, CX-5461 treatment did not result in histological change in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174). | 27486174 |
| BRIP1 C283S | Advanced Solid Tumor | sensitive | CX-5461 | Preclinical - Cell culture | Actionable | In a preclinical study, CX-5461 inhibited survival of transformed cells expressing BRIP1 C283S in culture (PMID: 32542039). | 32542039 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04890613 | Phase I | CX-5461 | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Recruiting | USA | CAN | 0 |
CKB BOOST